1064137-50-3 Usage
Uses
Used in Pharmaceutical Industry:
2,5-Dichloroquinoline-3-carbaldehyde is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows it to be a versatile component in the creation of new medicinal agents, contributing to the development of novel treatments and therapies.
Used in Chemical Research and Development:
In the realm of research and development, 2,5-Dichloroquinoline-3-carbaldehyde serves as an essential compound for exploring new chemical reactions and syntheses. It aids scientists in understanding the properties and behaviors of related chemical entities, thus propelling advancements in the chemical sciences.
Used in Agrochemical Production:
2,5-Dichloroquinoline-3-carbaldehyde is employed as a component in the production of agrochemicals. Its incorporation in these products is instrumental in developing effective solutions for agricultural applications, such as pest control and crop protection, thereby supporting sustainable farming practices.
Used in Dye Manufacturing:
2,5-Dichloroquinoline-3-carbaldehyde also finds application in the manufacturing of dyes. Its chemical properties make it suitable for the creation of diverse colorants used across various industries, including textiles, plastics, and printing inks, enriching the spectrum of color options available.
Used in Specialty Chemicals:
2,5-Dichloroquinoline-3-carbaldehyde is a vital ingredient in the formulation of specialty chemicals. Its presence in these products enables specific functionalities that are tailored to meet the unique requirements of different industries, showcasing its multifaceted utility in chemical innovation.
Check Digit Verification of cas no
The CAS Registry Mumber 1064137-50-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,4,1,3 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1064137-50:
(9*1)+(8*0)+(7*6)+(6*4)+(5*1)+(4*3)+(3*7)+(2*5)+(1*0)=123
123 % 10 = 3
So 1064137-50-3 is a valid CAS Registry Number.
1064137-50-3Relevant articles and documents
IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
-
Paragraph 0565; 0566, (2019/10/20)
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
-
Paragraph 0719-0720, (2019/10/17)
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
Page/Page column 70, (2008/12/04)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.
